Eugenia Capozzi
Centra
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eugenia Capozzi.
American Journal of Pathology | 1999
Riccardo Dolcetti; Alessandra Viel; Claudio Doglioni; Antonio Russo; Massimo Guidoboni; Eugenia Capozzi; Nicola Vecchiato; Ettore Macri; Mara Fornasarig; Mauro Boiocchi
Microsatellite instability (MSI) characterizes colorectal carcinomas (CRCs) in hereditary nonpolyposis colorectal cancer (HNPCC) syndrome and a proportion of sporadic CRCs. These MSI+ CRCs share several clinicopathological features, including a reputation for better survival rates than MSI- cases and a pronounced stromal inflammatory reaction of still undefined nature. In the present study, the presence, spatial distribution, and activation status of infiltrating cytotoxic effectors were investigated comparatively in 18 MSI+ and 37 MSI- CRCs by immunohistochemistry. The frequency of apoptosis was also evaluated by morphology and in situ end-labeling. MSI+ cases carried significantly higher numbers of cytotoxic lymphocytes infiltrating within neoplastic epithelial structures, as shown by immunostaining for CD3 (15.1 +/- 6.2 versus 4.6 +/- 4.1, P < 0.001), CD8 (13 +/- 6.4 versus 3.7 +/- 3.8, P < 0.001), and TIA-1 (11.2 +/- 6.5 versus 1.9 +/- 1.7, P < 0.001). These cytotoxic effectors were globally more activated in MSI+ than in MSI- tumors, as revealed by the expression of granzyme B (5.3 +/- 4.5 versus 0.6 +/- 1.3, P < 0.001). In MSI+ CRCs, the number of intraepithelial activated cytotoxic lymphocytes was significantly correlated with the proximal location of the tumor, a poorly differentiated phenotype, and the presence of peritumor lymphoid nodules. Multivariate analysis revealed that MSI was the major determinant of the presence of activated cytotoxic intraepithelial lymphocytes. Moreover, MSI+ CRCs also showed a significantly higher percentage of tumor cells undergoing apoptotic cell death (4.1 +/- 2.1 versus 2.6 +/- 1.1, P < 0.0001, by the TUNEL method), often located in close proximity of activated cytotoxic lymphocytes. These results are consistent with the presence of anti-tumor cytotoxic immune responses in most of MSI+ CRCs, a phenomenon that may at least in part contribute to the survival advantage ascribed to these patients.
Genes, Chromosomes and Cancer | 1997
Alessandra Viel; Maurizio Genuardi; Eugenia Capozzi; Francesca Leonardi; Alfonso Bellacosa; Maria Paravatou-Petsotas; Maria Grazia Pomponi; Mara Fornasarig; Antonio Percesepe; Luca Roncucci; Maria Grazia Tamassia; Piero Benatti; Maurizio Ponz de Leon; Agostino Valenti; Marcello Covino; Marcello Anti; Mirto Foletto; Mauro Boiocchi; Giovanni Neri
Mismatch repair genes MSH2 and MLH1 are considered to be the two major genes that are responsible for hereditary nonpolyposis colorectal cancer (HNPCC). Germline heterozygous inactivating mutations of MSH2 and MLH1 have been identified previously in a substantial fraction of individuals who are predisposed genetically to colorectal carcinoma (CRC) and other tumors of the HNPCC spectrum. With the aim of determining the relevance of these two genes in the Italian population, we submitted to mutational analysis a set of 17 HNPCC families, all of which fulfilled the “Amsterdam criteria.” A combination of different techniques, including reverse transcription‐polymerase chain reaction (RT‐PCR) of long fragments and single‐strand conformation polymorphism (SSCP) on cDNA and genomic DNA, allowed the identification of ten molecular variants, seven of which are predicted to inactivate mismatch repair function. The mutated predisposing gene was MSH2 in two families and MLH1 in five other families. All of the mutations were characterized by DNA sequencing and appeared to involve different molecular mechanisms, such as short in‐frame and out‐of‐frame deletions, splicing errors, and nonsense mutations. This study also demonstrates that, in the Italian population, a considerable fraction of HNPCC families (at least 41%) is linked to MSH2 and MLH1 mutations. Genes Chromosom. Cancer 18:8–18, 1997.
Gut | 1999
de Leon Mp; Monica Pedroni; Piero Benatti; Antonio Percesepe; Di Gregorio C; Moira Foroni; Giuseppina Rossi; Maurizio Genuardi; Giovanni Neri; Francesca Leonardi; Alessandra Viel; Eugenia Capozzi; Mauro Boiocchi; Luca Roncucci
BACKGROUND Hereditary non-polyposis colorectal cancer (HNPCC) is one of the most common inherited disorders predisposing to cancer. The genes responsible for the disease have recently been cloned and characterised; their mutations induce a generalised genomic instability which is particularly evident at microsatellite loci (replication error (RER)+ phenotype). AIMS To investigate how to select individuals and families in the general population who should be screened for constitutional mutations predisposing to colorectal cancer. PATIENTS/METHODS Between 1984 and 1995, 1899 colorectal malignancies in 1831 patients were registered, and in 1721 of these (94%), family trees could be obtained. Patients and families were classified into five categories according to a more or less likely genetic basis: HNPCC; “suspected” HNPCC; juvenile cases; aspecific cancer aggregation; sporadic cases. In 18 families with HNPCC as well as in 18 with suspected HNPCC, microsatellite instability in tumour tissues and constitutional mutations of two DNA mismatch repair genes (MSH2 and MLH1) could be evaluated. RER status was studied with five markers (BAT40, D2S123,D18S57, D17S787, and BAT26) in paraffin embedded tissues. Germline mutations of MSH2 orMLH1 genes were assessed on DNA and RNA extracted from lymphomonocytic cells, using reverse transcription polymerase chain reaction, single strand conformation polymorphism analysis, and direct DNA sequencing. RESULTS HNPCC represented 2.6% and suspected HNPCC 4.6% of all registered colorectal neoplasms. Eleven out of 18 HNPCC families (61%) showed microsatellite instability as opposed to four (of 18) suspected HNPCC (22%; p<0.02). Three germline mutations (two inMSH2 and one inMLH1 gene) were found in three different large HNPCC families, whereas no mutations were detected in suspected HNPCC. CONCLUSIONS In this study of cancer genetic epidemiology, data from a tumour registry were analysed and this ultimately led to the identification and selection of families that should be tested for mutator gene mutations. With the use of a population based approach, the incidence of mutations was appreciably lower than previously reported and limited to families with full blown HNPCC. It is possible that in most families with a clinical spectrum of HNPCC (or suspected HNPCC) other DNA mismatch repair genes are involved in the pathogenesis of the disease.
Human Genetics | 1998
Maurizio Genuardi; Alessandra Viel; Daniela Bonora; Eugenia Capozzi; Alfonso Bellacosa; Francesca Leonardi; Roberta Valle; Andrea Ventura; Monica Pedroni; Mauro Boiocchi; G. Neri
Abstract The phenomenon of alternative splicing in the DNA mismatch repair genes MLH1 and MSH2 was extensively investigated by coupled reverse transcription-polymerase chain reaction in different human tissues, including 42 mononuclear blood cell samples – 31 obtained from familial colon cancer patients or their at-risk relatives and 11 from healthy blood donors – 7 normal colonic mucosae, 4 established human cancer cell lines, 8 colorectal tumors, and one sample each of ileum, liver, muscle, thymus, breast, and EBV-transformed lymphoblasts. Several isoforms were observed for each gene. Products of MLH1 alternative splicing included mRNAs lacking alternative exons 6/9, 9, 9/10, 9/10/11, 10/11, 12, 16, and 17. For MSH2, products lacking exons 5, 13, 2 through 7, and 2 through 8 were identified. The levels of expression were found to vary among different samples. All isoforms were found in a relevant fraction (43–100%) of the mononuclear blood cell samples, as well as in other tissues. The splicing variants were also detected in normal colonic mucosa, with the exceptions of the MLH1–6/9 and –10/11 and the MSH2–13 isoforms. Germline mutations of MLH1 and MSH2 confer constitutional predisposition to the development of colorectal cancer and other neoplasms. A substantial proportion of the mutations identified so far involve alterations of the normal splicing process. Knowledge of the existence of multiple alternative splicing events, not caused by genomic DNA changes, is important for the evaluation of the results of molecular diagnostic tests based on RNA analysis.
International Journal of Cancer | 1998
Maurizio Genuardi; Marcello Anti; Eugenia Capozzi; Francesca Leonardi; Mara Fornasarig; Elisabetta Novella; Alfonso Bellacosa; Agostino Valenti; Giovanni Gasbarrini; Luca Roncucci; Piero Benatti; Antonio Percesepe; Maurizio Ponz de Leon; Claudio Coco; Antonio de Paoli; Maurizio Valentini; Mauro Boiocchi; Giovanni Neri; Alessandra Viel
Genetic diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC) may have a significant impact on the clinical management of patients and their at‐risk relatives. At present, clinical criteria represent the simplest and most useful method for the identification of HNPCC families and for the selection of candidates for genetic testing. However, reports of mismatch repair (MMR) gene mutations in families not fulfilling the minimal diagnostic criteria point out the necessity to identify additional clinical parameters suggestive of genetic predisposition to colorectal cancer (CRC) related to MMR defects. We thus investigated a series of 32 Italian putative HNPCC individuals selected on the basis of one of the following criteria: 1) family history of CRC and/or other extracolonic tumors; 2) early‐onset CRC; and 3) presence of multiple primary malignancies in the same individual. These patients were investigated for the presence of MLH1 and MSH2 mutations by single‐strand conformation polymorphism analysis. Pathogenetic truncating mutations were identified in 4 (12.5%) cases, 3 of them involving MSH2 and 1 MLH1. In addition, 2 missense MLH1 variants of uncertain significance were observed. All pathogenetic mutations were associated with early age (<40 years) at onset and proximal CRC location. Our results support the contention that constitutional MMR mutations can also occur in individuals without the classical HNPCC pattern. Moreover, evaluation of the clinical parameters associated with MMR mutations indicates that early onset combined with CRC location in the proximal colon can be definitely considered suggestive of MMR‐related hereditary CRC and should be included among the guidelines for referring patients for genetic testing. Int. J. Cancer 75:835–839, 1998.
Public Health Genomics | 1998
Alessandra Viel; Maurizio Genuardi; Emanuela Lucci-Cordisco; Eugenia Capozzi; Valentina Rovella; Mara Fornasarig; Maurizio Ponz de Leon; Marcello Anti; Monica Pedroni; Alfonso Bellacosa; Antonio Percesepe; Marcello Covino; Piero Benatti; Laura Del Tin; Luca Roncucci; Maurizio Valentini; Mauro Boiocchi; Giovanni Neri
Objective: Identification of clinical and molecular characteristics associated with constitutional MLH1 and MSH2 mutations and definition of a stepwise strategy for the selection of colorectal cancer (CRC) patients amenable to MLH1 and MSH2 genetic testing. Methods: 90 unrelated CRC patients were initially selected on the basis of either familial or early onset occurrence of CRC. They were screened for the presence of constitutional MLH1 and MSH2 mutations and for microsatellite instability (MSI). Results: 16 pathogenetic mutations (9 MLH1 and 7 MSH2) were identified in 41% of Amsterdam hereditary nonpolyposis colorectal cancer (HNPCC) families, 5% of suspected HNPCC families, and 14% of sporadic early-onset CRC patients. The presence of the mutations correlated with MSI, with early age of onset and proximal location of the tumor, and with the presence of some extracolonic tumors of the HNPCC spectrum and/or multiple tumors in the family. Conclusions: Evaluation of clinical and molecular characteristics is useful for the identification of candidates to MLH1 and MSH2 mutational analysis and allows the application of a rational approach to genetic testing.
Public Health Genomics | 1998
Maurizio Ponz de Leon; Marcello Anti; Monica Pedroni; Alfonso Bellacosa; Antonio Percesepe; Marcello Covino; Piero Benatti; Laura Del Tin; Luca Roncucci; Maurizio Valentini; Mauro Boiocchi; Giovanni Neri; Howard J. Allen; César A. Briceño; M.Steven Piver; Piero C. Giordano; C. L. Harteveld; Angelien J.G.M. Heister; D. Batelaan; Peter van Delft; Rob Plug; Monique Losekoot; Luigi F. Bernini; A.E. Czeizel; M. Dobó; I. Dudás; Z. Gasztonyi; I. Lantos; Cynthia A. James; Gail Geller
93 Translating Advances in Human Genetics into Disease Prevention and Health Promotion. First Annual Conference on Genetics and Public Health, Atlanta, Ga., May 13–15, 1998 Khoury, M.J. (Atlanta, Ga.); Puryear, M. (Rockville, Md.); Thomson, E. (Bethesda, Md.); Bryan, J. (Washington, D.C.) 109 Book Review No. 1
International Journal of Cancer | 1994
Alessandra Viel; Franca Giannini; Eugenia Capozzi; Vincenzo Canzonieri; Carlo Scarabelli; A Gloghini; Mauro Boiocchi
Cancer Research | 1995
Alessandra Viel; Lara Dall'Agnese; Vincenzo Canzonieri; Francesco Sopracordevole; Eugenia Capozzi; Antonino Carbone; Maria Caterina Visentin; Mauro Boiocchi
International Journal of Oncology | 1998
Alessandra Viel; E Novella; Maurizio Genuardi; Eugenia Capozzi; Mara Fornasarig; Monica Pedroni; Manuela Santarosa; M P De Leon; L Della Puppa; Marcello Anti; Mauro Boiocchi